Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis.

What was studied

This review looked at ropeginterferon in myeloproliferative neoplasms. It was used mainly in polycythemia vera. The team searched 3 databases. It included clinical and real-world studies. 18 studies with 1,836 patients were included. The team pooled response and safety data.

What they found

Complete hematologic response rose over time. It was higher at 12 months than at 3 months. Molecular response was seen in a smaller share of patients. Results for it varied a lot across studies. JAK2 allele burden fell across studies. Spleen size and symptoms improved in several cohorts. Serious low blood counts were uncommon. Severe liver harm was uncommon. Most adverse events were mild. Few patients stopped treatment.

What it means for patients

The authors say the drug shows favorable efficacy and safety. This was most true in polycythemia vera. Blood and molecular responses grew over time. They see it as a possible disease-modifying therapy.

Why it is not certain yet

The authors call for more standardized, long-term studies. These should focus on ET and MF. Molecular results varied a lot across studies. Many outcomes were put together in words.

Source

Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.